Investment of $125 Million in Series B for ForSight Robotics, focusing on advanced technology for robotic eye surgery

In a significant stride for the ophthalmic surgery industry, ForSight Robotics is set to begin robotic cataract surgery clinical trials in the coming year. The company's groundbreaking technology, the ORYOM Platform, is engineered for precise and consistent ophthalmic procedures, marking a potential game-changer in eye care.

The ORYOM Platform leverages AI-based algorithms, advanced computer vision, and micromechanics to deliver unprecedented dexterity and maneuverability. This innovative technology is designed to address a massive, underserved market in ophthalmic surgery, positioning ForSight Robotics to set a new standard in eye care and drive innovation on a global scale.

The latest funding round, a $125 million Series B led by Eclipse, underscores the extraordinary potential impact of ForSight Robotics' technology on global eye care. Seth Winterroth, partner at Eclipse, acknowledges the company as being at the forefront of a transformation in surgical robotics.

The funding will accelerate the next growth phase for the ORYOM Platform, including the launch of first-in-human clinical trials this year. Over two dozen ophthalmic surgeons have already completed hundreds of procedures on animal eye models with the ORYOM Platform, demonstrating its potential efficacy.

ForSight Robotics' strategic advisory board includes Dr. Fred Moll, the founder of Intuitive Surgical and the da Vinci surgical system, and Rony Abovitz, the founder of MAKO Surgical Corp. Dr. Joseph Nathan, co-founder of ForSight Robotics, believes that the technology, designed for the unique precision and complexity of eye surgery, has the potential to bring a similar level of transformative impact to eye surgery as Intuitive Surgical did to general surgery.

The opportunity ahead for ForSight Robotics, according to Dr. Nathan, is immense due to the comparable market size and an urgent global need. The company has expanded its executive team, received ISO 13485:2016 certification, and doubled in size, surpassing 110 employees.

The funding round also included participation from an undisclosed strategic investor, Dr. Fred Moll, the Adani Group, Reiya Ventures, and existing investors. Despite the identity of the strategic investor remaining undisclosed, the participation underscores the broad-based support for ForSight Robotics' mission to revolutionize eye care.

Dr. Nathan expresses optimism about ophthalmology being the next frontier in the robotics revolution. With the ORYOM Platform's ability to reach any point within the human eye, enabling surgeons to navigate complex angles and access both anterior and posterior segments, the future of eye surgery looks promising. As ForSight Robotics embarks on its clinical trials, the world watches with anticipation for this potential breakthrough in eye care.